0001104659-23-081677.txt : 20230717
0001104659-23-081677.hdr.sgml : 20230717
20230717170440
ACCESSION NUMBER: 0001104659-23-081677
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230713
FILED AS OF DATE: 20230717
DATE AS OF CHANGE: 20230717
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HENDERSON MICHAEL THOMAS
CENTRAL INDEX KEY: 0001779990
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41740
FILM NUMBER: 231092262
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apogee Therapeutics, Inc.
CENTRAL INDEX KEY: 0001974640
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 880588063
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 221 CRESCENT ST.
STREET 2: BUILDING 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 650-394-5230
MAIL ADDRESS:
STREET 1: 221 CRESCENT ST.
STREET 2: BUILDING 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
FORMER COMPANY:
FORMER CONFORMED NAME: Apogee Therapeutics, LLC
DATE OF NAME CHANGE: 20230420
3/A
1
tm2321456-3_3aseq1.xml
OWNERSHIP DOCUMENT
X0206
3/A
2023-07-13
2023-07-13
0
0001974640
Apogee Therapeutics, Inc.
APGE
0001779990
HENDERSON MICHAEL THOMAS
C/O APOGEE THERAPEUTICS, INC.
221 CRESCENT ST., BLDG. 17, STE. 102B
WALTHAM
MA
02453
1
1
0
0
Chief Executive Officer
Common Stock
1489487
D
Includes (i) 851,495 shares of restricted common stock, which vest in 34 equal monthly installments through May 2, 2026, and (ii) 287,377 shares of restricted common stock, one quarter of which will vest on December 14, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, in each case subject to the Reporting Person's continued service to the Issuer.
This amendment is being filed to correct the number of shares reported in Table I due to a calculation error.
/s/ Jane Pritchett Henderson, as attorney-in-fact for Michael Henderson
2023-07-17